Premium
Integrating Molecular Medicine into the US Health‐care System: Opportunities, Barriers, and Policy Challenges
Author(s) -
Deverka P A,
Doksum T,
Carlson R J
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100319
Subject(s) - health care , psychological intervention , variety (cybernetics) , precision medicine , medicine , business , nursing , engineering ethics , political science , computer science , engineering , pathology , artificial intelligence , law
Scientific support about the concept of using molecular data for risk stratification and tailoring health‐care interventions to the individual—a strategy broadly defined as molecular medicine (MM)—is accumulating. Molecular‐based health‐care technologies are beginning to enter clinical practice, but their use has revealed many scientific, economic, and organizational barriers to the effective delivery of targeted health care. We conducted a qualitative interview study to describe the MM landscape, with an emphasis on eliciting policy recommendations for the field from a broad range of stakeholders in MM and health care. Molecular medicine has widespread support but will require changes in how molecular‐based technologies are evaluated, how health care is financed and delivered, and how clinicians and consumers are trained and prepared for its use. In particular, researchers and developers need to become active participants in a variety of clinical integration strategies to realize the promise of MM. Clinical Pharmacology & Therapeutics (2007) 82 , 427–434; doi: 10.1038/sj.clpt.6100319 ; published online 8 August 2007